{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:17:56Z","timestamp":1758759476056,"version":"3.44.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"publisher","award":["Mu-Phar-23-24","Mu-Phar-23-24","Mu-Phar-23-24","Mu-Phar-23-24","Mu-Phar-23-24"],"award-info":[{"award-number":["Mu-Phar-23-24","Mu-Phar-23-24","Mu-Phar-23-24","Mu-Phar-23-24","Mu-Phar-23-24"]}],"id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This prospective study aimed at investigating the role of immune-related gene expression (GATA3, METTL3, ERCC2, PD-L1 and IFN-\u03b3) in the prediction of response to platinum-based neoadjuvant chemotherapy (NAC) in treatment of muscle-invasive bladder cancer (MIBC). A total of 112 patients received four cycles of systemic cisplatin-based NAC and then were subjected to radiological and histopathological evaluation through taking bladder biopsy before surgery. Quantitative real-time RT-PCR assessed GATA3, METTL3 and ERCC2 mRNA expression in tissue samples. Immunohistochemical (IHC) staining was done for GATA3, PD-L1 and IFN-\u03b3 in tissue samples. Out of the 112 patients, only 104 completed the proposed protocol of systemic NAC and were included in the final analysis. Out of 104 patients, 43 (41.4%) were responders and the remaining 61 patients (58.6%) were assigned as non-responders. GATA3 and IFN-\u03b3 expressions were significantly higher in tumor tissue of the responders compared to non-responders. METTL3 and ERCC2 expressions were significantly lower in tumor tissue of the responders compared to non-responders, whereas, PD-L1 staining showed no significant difference between both groups. Our study suggests that GATA3, METTL3, ERCC2, and IFN-\u03b3 could serve as predictive biomarkers for NAC response in MIBC patients. Higher GATA3 and IFN-\u03b3 along with lower METTL3 and ERCC2 levels are positively correlated with better response to NAC. <\/jats:p>","DOI":"10.1007\/s00262-025-04135-8","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:14:13Z","timestamp":1753874053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of response to neoadjuvant chemotherapy in patients with muscle-invasive urothelial bladder cancer: role of immune-related gene expression"],"prefix":"10.1007","volume":"74","author":[{"given":"Hadeer","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer M.","family":"Abd El-Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Ezzat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hany Ibrahim","family":"Kenawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A.","family":"Shokeir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"4135_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00345-018-2436-y","volume":"37","author":"MI Fern\u00e1ndez","year":"2019","unstructured":"Fern\u00e1ndez MI, Brausi M, Clark PE, Cookson MS, Grossman HB, Khochikar M et al (2019) Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD\u2013SIU joint consultation on bladder cancer. World J Urol 37:3\u201313","journal-title":"World J Urol"},{"issue":"4","key":"4135_CR2","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.euf.2019.10.016","volume":"6","author":"G Motterle","year":"2020","unstructured":"Motterle G, Andrews JR, Morlacco A, Karnes RJ (2020) Predicting response to neoadjuvant chemotherapy in bladder cancer. Eur Urol Focus 6(4):642\u2013649","journal-title":"Eur Urol Focus"},{"issue":"1","key":"4135_CR3","first-page":"9962397","volume":"2022","author":"H Luo","year":"2022","unstructured":"Luo H, Liu G-L, Jian D, Liang D-D, Li X-M, Zhong L et al (2022) Neoadjuvant chemotherapy improves the immunosuppressive microenvironment of bladder cancer and increases the sensitivity to immune checkpoint blockade. J Immunol Res 2022(1):9962397","journal-title":"J Immunol Res"},{"key":"4135_CR4","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2017.06.48","author":"HW Kang","year":"2017","unstructured":"Kang HW, Kim W-J, Yun SJ (2017) The role of the tumor microenvironment in bladder cancer development and progression. Transl Cancer Res. https:\/\/doi.org\/10.21037\/tcr.2017.06.48","journal-title":"Transl Cancer Res"},{"key":"4135_CR5","doi-asserted-by":"publisher","first-page":"1155244","DOI":"10.3389\/fonc.2023.1155244","volume":"13","author":"A Font","year":"2023","unstructured":"Font A, Domenech M, Ramirez JL, Marqu\u00e9s M, Ben\u00edtez R, Ruiz de Porras V et al (2023) Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features. Front Oncol 13:1155244","journal-title":"Front Oncol"},{"issue":"1","key":"4135_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12964-023-01360-5","volume":"21","author":"Q Jin","year":"2023","unstructured":"Jin Q, Qu H, Quan C (2023) New insights into the regulation of METTL3 and its role in tumors. Cell Commun Signal 21(1):334","journal-title":"Cell Commun Signal"},{"issue":"1","key":"4135_CR7","doi-asserted-by":"publisher","first-page":"21186","DOI":"10.1038\/s41598-021-00628-5","volume":"11","author":"T Bejrananda","year":"2021","unstructured":"Bejrananda T, Kanjanapradit K, Saetang J, Sangkhathat S (2021) Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5\/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer. Sci Rep 11(1):21186","journal-title":"Sci Rep"},{"issue":"3","key":"4135_CR8","first-page":"386","volume":"7","author":"Z Yang","year":"2021","unstructured":"Yang Z, Shen Z, Jin D, Zhang N, Wang Y, Lei W et al (2021) Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. J Clin Transl Res 7(3):386","journal-title":"J Clin Transl Res"},{"issue":"11","key":"4135_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1644108","volume":"8","author":"S Wahlin","year":"2019","unstructured":"Wahlin S, Nodin B, Leandersson K, Boman K, Jirstr\u00f6m K (2019) Clinical impact of T cells, B cells and the PD-1\/PD-L1 pathway in muscle invasive bladder cancer: a comparative study of transurethral resection and cystectomy specimens. Oncoimmunology 8(11):e1644108","journal-title":"Oncoimmunology"},{"issue":"4","key":"4135_CR10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.eururo.2022.07.023","volume":"83","author":"A Gil-Jimenez","year":"2023","unstructured":"Gil-Jimenez A, van Dorp J, Contreras-Sanz A, van der Vos K, Vis DJ, Braaf L et al (2023) Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer. Eur Urol 83(4):313\u2013317","journal-title":"Eur Urol"},{"issue":"4","key":"4135_CR11","volume":"2","author":"KCE Lee","year":"2019","unstructured":"Lee KCE, Mui WH, Chan W, Wong CSF, Chu SKP (2019) Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: a retrospective analysis of the patient and treatment factors in a single institute. Cancer Rep 2(4):e1170","journal-title":"Cancer Rep"},{"issue":"4","key":"4135_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212 \u0394\u0394CT method. Methods 25(4):402\u2013408","journal-title":"Methods"},{"key":"4135_CR13","doi-asserted-by":"crossref","unstructured":"Al-Sabawy HB, Rahawy AM, Al-Mahmood SS (2021) Standard techniques for formalin-fixed paraffin-embedded tissue: a pathologist\u2019s perspective","DOI":"10.33899\/ijvs.2021.131918.2023"},{"issue":"5","key":"4135_CR14","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1111\/jcmm.14280","volume":"23","author":"S Cheng","year":"2019","unstructured":"Cheng S, Qian K, Wang Y, Wang G, Liu X, Xiao Y et al (2019) Ppar\u03b3 inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells. J Cell Mol Med 23(5):3724\u20133736","journal-title":"J Cell Mol Med"},{"issue":"1","key":"4135_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13000-023-01295-y","volume":"18","author":"DS Helal","year":"2023","unstructured":"Helal DS, Darwish SA, Awad RA, Ali DA, El-Guindy DM (2023) Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival. Diagn Pathol 18(1):11","journal-title":"Diagn Pathol"},{"issue":"1","key":"4135_CR16","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.21608\/ejhm.2022.223167","volume":"87","author":"FE-ZSE-D Yassin","year":"2022","unstructured":"Yassin FE-ZSE-D, Shehata CGG, El-Deen EMS (2022) Programmed cell death ligand 1 (PD-L1) expression in molecular subtypes of breast cancer. Egypt J Hosp Med 87(1):1226\u20131235","journal-title":"Egypt J Hosp Med"},{"issue":"1","key":"4135_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4132\/jptm.2020.09.29","volume":"55","author":"T Jeon","year":"2021","unstructured":"Jeon T, Kim A, Kim C (2021) Automated immunohistochemical assessment ability to evaluate estrogen and progesterone receptor status compared with quantitative reverse transcription-polymerase chain reaction in breast carcinoma patients. J Pathol Transl Med 55(1):33\u201342","journal-title":"J Pathol Transl Med"},{"issue":"4","key":"4135_CR18","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1002\/cam4.1979","volume":"8","author":"H Su","year":"2019","unstructured":"Su H, Jiang H, Tao T, Kang X, Zhang X, Kang D et al (2019) Hope and challenge: precision medicine in bladder cancer. Cancer Med 8(4):1806\u20131816","journal-title":"Cancer Med"},{"issue":"9","key":"4135_CR19","doi-asserted-by":"publisher","first-page":"7867","DOI":"10.1007\/s11033-023-08689-7","volume":"50","author":"L Schwarzova","year":"2023","unstructured":"Schwarzova L, Varchulova Novakova Z, Danisovic L, Ziaran S (2023) Molecular classification of urothelial bladder carcinoma. Mol Biol Rep 50(9):7867\u20137877","journal-title":"Mol Biol Rep"},{"issue":"4","key":"4135_CR20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.tranon.2019.01.005","volume":"12","author":"D Sikic","year":"2019","unstructured":"Sikic D, Wirtz RM, Wach S, Dyrskj\u00f8t L, Erben P, Bolenz C et al (2019) Androgen receptor mRNA expression in urothelial carcinoma of the bladder: a retrospective analysis of two independent cohorts. Transl Oncol 12(4):661\u2013668","journal-title":"Transl Oncol"},{"issue":"4","key":"4135_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4161\/cbt.27631","volume":"15","author":"Y Li","year":"2014","unstructured":"Li Y, Ishiguro H, Kawahara T, Kashiwagi E, Izumi K, Miyamoto H (2014) Loss of GATA3 in bladder cancer promotes cell migration and invasion. Cancer Biol Ther 15(4):428\u2013435","journal-title":"Cancer Biol Ther"},{"key":"4135_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.860663","volume":"9","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Qi T, Long Y, Li X, Yao Y, Wu Q et al (2022) Gata3 predicts the tumor microenvironment phenotypes and molecular subtypes for bladder carcinoma. Front Surg 9:860663","journal-title":"Front Surg"},{"issue":"19","key":"4135_CR23","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1038\/s41388-019-0683-z","volume":"38","author":"M Cheng","year":"2019","unstructured":"Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M et al (2019) The m6A methyltransferase METTL3 promotes bladder cancer progression via AFF4\/NF-\u03baB\/MYC signaling network. Oncogene 38(19):3667\u20133680","journal-title":"Oncogene"},{"issue":"7","key":"4135_CR24","doi-asserted-by":"publisher","first-page":"e28165","DOI":"10.1016\/j.heliyon.2024.e28165","volume":"10","author":"Y Huang","year":"2024","unstructured":"Huang Y, Lv Y, Yang B, Zhang S, Zhang C, Hu W et al (2024) Enhancing m6A modification of lncRNA through METTL3 and RBM15 to promote malignant progression in bladder cancer. Heliyon 10(7):e28165","journal-title":"Heliyon"},{"key":"4135_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-1036-9","volume":"18","author":"J Han","year":"2019","unstructured":"Han J, Wang J-Z, Yang X, Yu H, Zhou R, Lu H-C et al (2019) METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221\/222 maturation in m6A-dependent manner. Mol Cancer 18:1\u201315","journal-title":"Mol Cancer"},{"key":"4135_CR26","doi-asserted-by":"publisher","first-page":"1047481","DOI":"10.3389\/fgene.2022.1047481","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, Hu J, Zu X, Chen M, Chen J, Zou Y et al (2022) A novel signature to predict the neoadjuvant chemotherapy response of bladder carcinoma: results from a territory multicenter real-world study. Front Genet 13:1047481","journal-title":"Front Genet"},{"issue":"10","key":"4135_CR27","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H et al (2014) Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4(10):1140\u20131153","journal-title":"Cancer Discov"},{"issue":"1","key":"4135_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5301\/jbm.5000186","volume":"31","author":"M Zafeer","year":"2016","unstructured":"Zafeer M, Mahjabeen I, Kayani MA (2016) Increased expression of ERCC2 gene in head and neck cancer is associated with aggressive tumors: a systematic review and case-control study. Int J Biol Markers 31(1):17\u201325","journal-title":"Int J Biol Markers"},{"key":"4135_CR29","unstructured":"Acedo-Terrades A, Rodriguez-Vida A, Buisan O, Bodalo-Torruella M, Gabarros M, Claros M, et al. (2024) Predicting response to cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer: transcriptomic features outrank genomic biomarkers. 28, 24309634."},{"issue":"7","key":"4135_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071784","volume":"12","author":"A Font","year":"2020","unstructured":"Font A, Dom\u00e8nech M, Ben\u00edtez R, Rava M, Marqu\u00e9s M, Ram\u00edrez J et al (2020) Immunohistochemistry-based taxonomical classification of bladder cancer predicts response to neoadjuvant chemotherapy. Cancers (Basel) 12(7):1784","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4135_CR31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","volume":"69","author":"FH Groenendijk","year":"2016","unstructured":"Groenendijk FH, de Jong J, van de Putte EEF, Michaut M, Schlicker A, Peters D et al (2016) ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 69(3):384\u2013388","journal-title":"Eur Urol"},{"issue":"8","key":"4135_CR32","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/13543784.2021.1948999","volume":"30","author":"I Bin Riaz","year":"2021","unstructured":"Bin Riaz I, Khan AM, Catto JW, Hussain SA (2021) Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. Expert Opin Investig Drugs 30(8):837\u2013855","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"4135_CR33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ajpath.2019.10.018","volume":"190","author":"R Pichler","year":"2020","unstructured":"Pichler R, Lindner AK, Comp\u00e9rat E, Obrist P, Sch\u00e4fer G, Todenh\u00f6fer T et al (2020) Amplification of 7p12 is associated with pathologic nonresponse to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Am J Pathol 190(2):442\u2013452","journal-title":"Am J Pathol"},{"issue":"1","key":"4135_CR34","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41598-021-04678-7","volume":"12","author":"E Olkhov-Mitsel","year":"2022","unstructured":"Olkhov-Mitsel E, Hodgson A, Liu SK, Vesprini D, Bayani J, Bartlett JM et al (2022) Upregulation of IFN\u03b3-mediated chemokines dominate the immune transcriptome of muscle-invasive urothelial carcinoma. Sci Rep 12(1):716","journal-title":"Sci Rep"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04135-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04135-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04135-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:03:16Z","timestamp":1758729796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04135-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["4135"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04135-8","relation":{},"ISSN":["1432-0851"],"issn-type":[{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Research Ethics Committee of our institution (Ethical Approval Code 2024-234). Written informed consent was obtained from all patients. The study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"279"}}